Article
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
BMC cancer - 22 Mar 2012
Rutkowski Piotr, Bylina Elżbieta, Klimczak Anna, Switaj Tomasz, Falkowski Sławomir, Kroc Jacek, Lugowska Iwona, Brzeskwiniewicz Magdalena, Melerowicz Wojciech, Osuch Czesław, Mierzejewska Ewa, Wasielewski Kacper, Woźniak Agnieszka, Grzesiakowska Urszula, Nowecki Zbigniew I, Siedlecki Janusz A, Limon Janusz
Abstract excerpt
BACKGROUND: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event related to SU, reported as predictive factor in renal cell carcinoma. The aim of the study was to analyze the outcomes and factors predicting results of SU therapy in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.